| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | NaN | NaN | NaN | 0 |
| Research and development | 684,000 | 538,000 | 608,000 | 496,000 |
| General and administrative | 1,006,000 | 877,000 | 827,000 | 960,000 |
| Total operating expenses | 1,690,000 | 1,415,000 | 1,435,000 | 1,456,000 |
| Loss from operations | -1,690,000 | -1,415,000 | -1,435,000 | -1,456,000 |
| Interest income | 36,000 | 50,000 | 37,000 | 34,000 |
| Interest expense | NaN | NaN | NaN | 0 |
| Debt discount amortization | NaN | NaN | NaN | 0 |
| Total other income | 36,000 | 50,000 | 37,000 | 34,000 |
| Net loss | -1,654,000 | -1,365,000 | -1,398,000 | -1,422,000 |
| Basic EPS | -0.08 | -0.067 | -0.07 | -0.08 |
| Diluted EPS | -0.08 | -0.067 | -0.07 | -0.08 |
| Basic Average Shares | 21,010,132 | 20,416,613 | 20,206,033 | 17,213,017 |
| Diluted Average Shares | 21,010,132 | 20,416,613 | 20,206,033 | 17,213,017 |
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)